EUVIMEDEUVIMED entdecken
Crossref

Cangrelor: Safe and Effective for Left Ventricular Assist Device Thrombosis

Roopa Rao, Eve Anderson, Mark Jones, Muhamed Safiia, Maya Guglin

The VAD Journal · 2020

DOI: 10.11589/vad/e2020621 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The VAD Journal, 2020. Verfasst von Roopa Rao und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pump thrombosis is a devastating complication of left ventricular assist device implantation as it increases the risk of mortality and morbidity. Early and effective treatment is important to prevent the progression of the clot and to avoid the surgical need for pump exchange or heart transplant. The current strategies of intensifying anticoagulation therapy are not consistently effective and carry significant bleeding risks. Cangrelor is a new pharmacological agent that has been utilized as an antiplatelet agent in several cardiac procedures. In this case series, we describe the use of cangrelor for left ventricular assist device thrombosis in five patients. Cangrelor appears to be a potentially safe and effective alternative strategy.

Zitieren

APA

Rao, R., Anderson, E., Jones, M., Safiia, M., & Guglin, M. (2020). Cangrelor: Safe and Effective for Left Ventricular Assist Device Thrombosis. The VAD Journal. https://doi.org/10.11589/vad/e2020621

Vancouver

Rao R, Anderson E, Jones M, Safiia M, Guglin M. Cangrelor: Safe and Effective for Left Ventricular Assist Device Thrombosis. The VAD Journal. 2020. doi:10.11589/vad/e2020621

BibTeX
@article{Rao2020,
  author = {Rao, Roopa and Anderson, Eve and Jones, Mark and Safiia, Muhamed and Guglin, Maya},
  title = {Cangrelor: Safe and Effective for Left Ventricular Assist Device Thrombosis},
  journal = {The VAD Journal},
  year = {2020},
  doi = {10.11589/vad/e2020621}
}
Kostenlos starten →